The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Survival Rate

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Survival Rate


Psychiatry related information on Survival Rate


High impact information on Survival Rate

  • Dual roles of FVE in regulating the flowering time and the cold response may have an evolutionary advantage for plants by increasing their survival rates [11].
  • RESULTS: The overall survival rate among the 10 recipients with ABO-incompatible donors was 80 percent, with 2 early deaths due to causes presumed to be unrelated to ABO incompatibility [12].
  • After three years, the survival rate was 85.7 percent with interferon and cytarabine and 79.1 percent with interferon alone [13].
  • In patients with stage II disease whose tumors expressed DCC, the five-year survival rate was 94.3 percent, whereas in patients with DCC-negative tumors, the survival rate was 61.6 percent (P<0.001) [14].
  • One year after enrollment, patients who received t-PA had both higher costs ($2,845) and a higher survival rate (an increase of 1.1 percent, or 11 per 1000 patients treated) than streptokinase-treated patients [15].

Chemical compound and disease context of Survival Rate


Biological context of Survival Rate


Anatomical context of Survival Rate


Associations of Survival Rate with chemical compounds

  • Thirty-five of the 43 patients given both methotrexate and cyclosporine and 31 of the 50 patients given cyclosporine are alive as of this writing, at 4 months to 2 years (median, 15 months); the actuarial survival rates in the two groups at 1.5 years were 80 percent and 55 percent, respectively (P = 0.042) [31].
  • For patients with bulbar-onset disease, one-year survival rates were 35 percent (6 of 17) with placebo and 73 percent (11 of 15) with riluzole (P = 0.014), whereas for those with limb-onset disease one-year survival was 64 percent and 74 percent, respectively (P = 0.17) [32].
  • For unknown reasons the survival rate of transplanted dopamine neurons is only around 10% in experimental animals [33].
  • None of the steroid regimens statistically improved mean group survival rate or neurological recovery rate over that observed in the group that did not receive steroids [34].
  • No significant difference was found in the 1-year survival rate of nimodipine-treated (30 [40%] of 75 patients) and placebo-treated patients (29 [36%] of 80 patients) [35].

Gene context of Survival Rate

  • Although mre-11/mre-11 animals derived from heterozygous parents are viable and produce many embryos, there is a marked drop both in the number and survivorship of embryos produced by succeeding generations [36].
  • Agtr1a-/-, Agtr1b-/- mice are characterized by normal in utero survival but decreased ex utero survival rate [37].
  • At three years, there was an 18% difference between the survival rates of grafts with 0 or 4 mismatches among transplants typed for HLA-A and B antigen splits whereas the difference in transplants typed for broad antigens was only 2% [38].
  • Five-year survival rates were 35% (95% confidence interval [CI], 23-47) and 72% (95% CI, 53-90) in COX-2 high and COX-2 low categories, respectively [39].
  • Mice harboring one decorin allele and no p53 gene developed the same spectrum of tumors as the double knockout animals, but had a survival rate similar to the p53 null animals (T50 approximately 6 months) [40].

Analytical, diagnostic and therapeutic context of Survival Rate

  • Survival rates after transplantation rose in the 1980s with the use of cyclosporine and have remained relatively consistent since then, although recipients older than 65 years or younger than 1 year have lower survival rates than recipients of other ages [41].
  • Daily injections of 0.1 mg naltrexone/kg, which invoked a receptor blockade for 6-8 hours/day, resulted in 31-92% delay in latency time prior to tumor expression and a 27-49% increase in mean survival time; the magnitude of antitumor response was governed by tumor burden [42].
  • Cyclosporine has been heralded as a potent, nonspecific immunosuppressive agent that will significantly improve renal allograft survival rates [43].
  • Recent clinical trials have shown that in stable hypoxemic patients (arterial O2 tension less than 60 torr) with obstructive disease, survival is prolonged by chronic O2 therapy, and that the more continuous the therapy is, the better the survival rate [44].
  • Newer means for the localization of small-size PLC (under 5 cm), such as type B ultrasonography, nuclide scanning, computerized tomography, and hepatoangiography, represent remarkable progress in improving markedly the success of surgery and hence the survival rate of PLC patients [45].


  1. The course and prognosis of different forms of chronic airways obstruction in a sample from the general population. Burrows, B., Bloom, J.W., Traver, G.A., Cline, M.G. N. Engl. J. Med. (1987) [Pubmed]
  2. A long-term prevention study with oxprenolol in coronary heart disease. Taylor, S.H., Silke, B., Ebbutt, A., Sutton, G.C., Prout, B.J., Burley, D.M. N. Engl. J. Med. (1982) [Pubmed]
  3. Mortality in persons with multiple sclerosis in the Seattle and Los Angeles areas. Malmgren, R.M., Dudley, J.P., Visscher, B.R., Valdiviezo, N.L., Clark, V.A., Detels, R. JAMA (1981) [Pubmed]
  4. Differences between black and white women with breast cancer in time from symptom recognition to medical consultation. Black/White Cancer Survival Study Group. Coates, R.J., Bransfield, D.D., Wesley, M., Hankey, B., Eley, J.W., Greenberg, R.S., Flanders, D., Hunter, C.P., Edwards, B.K., Forman, M. J. Natl. Cancer Inst. (1992) [Pubmed]
  5. Osteogenic protein-1 (bone morphogenetic protein-7) reduces severity of injury after ischemic acute renal failure in rat. Vukicevic, S., Basic, V., Rogic, D., Basic, N., Shih, M.S., Shepard, A., Jin, D., Dattatreyamurty, B., Jones, W., Dorai, H., Ryan, S., Griffiths, D., Maliakal, J., Jelic, M., Pastorcic, M., Stavljenic, A., Sampath, T.K. J. Clin. Invest. (1998) [Pubmed]
  6. Evidence for familial factors that protect against dementia and outweigh the effect of increasing age. Payami, H., Montee, K., Kaye, J. Am. J. Hum. Genet. (1994) [Pubmed]
  7. Circadian Clock mutation in dams disrupts nursing behavior and growth of pups. Hoshino, K., Wakatsuki, Y., Iigo, M., Shibata, S. Endocrinology (2006) [Pubmed]
  8. Seven-year survival rate after age 85 years: relation to Alzheimer disease and vascular dementia. Aevarsson, O., Svanborg, A., Skoog, I. Arch. Neurol. (1998) [Pubmed]
  9. 3-Nitropropionic acid produces striatum selective lesions accompanied by iNOS expression. Nishino, H., Fujimoto, I., Shimano, Y., Hida, H., Kumazaki, M., Fukuda, A. J. Chem. Neuroanat. (1996) [Pubmed]
  10. Treatments for COPD. Hanania, N.A., Ambrosino, N., Calverley, P., Cazzola, M., Donner, C.F., Make, B. Respiratory medicine. (2005) [Pubmed]
  11. A genetic link between cold responses and flowering time through FVE in Arabidopsis thaliana. Kim, H.J., Hyun, Y., Park, J.Y., Park, M.J., Park, M.K., Kim, M.D., Kim, H.J., Lee, M.H., Moon, J., Lee, I., Kim, J. Nat. Genet. (2004) [Pubmed]
  12. ABO-incompatible heart transplantation in infants. West, L.J., Pollock-Barziv, S.M., Dipchand, A.I., Lee, K.J., Cardella, C.J., Benson, L.N., Rebeyka, I.M., Coles, J.G. N. Engl. J. Med. (2001) [Pubmed]
  13. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. Guilhot, F., Chastang, C., Michallet, M., Guerci, A., Harousseau, J.L., Maloisel, F., Bouabdallah, R., Guyotat, D., Cheron, N., Nicolini, F., Abgrall, J.F., Tanzer, J. N. Engl. J. Med. (1997) [Pubmed]
  14. The DCC protein and prognosis in colorectal cancer. Shibata, D., Reale, M.A., Lavin, P., Silverman, M., Fearon, E.R., Steele, G., Jessup, J.M., Loda, M., Summerhayes, I.C. N. Engl. J. Med. (1996) [Pubmed]
  15. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. Mark, D.B., Hlatky, M.A., Califf, R.M., Naylor, C.D., Lee, K.L., Armstrong, P.W., Barbash, G., White, H., Simoons, M.L., Nelson, C.L. N. Engl. J. Med. (1995) [Pubmed]
  16. L651582: a novel antiproliferative and antimetastasis agent. Kohn, E.C., Liotta, L.A. J. Natl. Cancer Inst. (1990) [Pubmed]
  17. Antisense oligonucleotides directed against the viral RNA polymerase gene enhance survival of mice infected with influenza A. Mizuta, T., Fujiwara, M., Hatta, T., Abe, T., Miyano-Kurosaki, N., Shigeta, S., Yokota, T., Takaku, H. Nat. Biotechnol. (1999) [Pubmed]
  18. Combination of long-acting microcapsules of the D-tryptophan-6 analog of luteinizing hormone-releasing hormone with chemotherapy: investigation in the rat prostate cancer model. Schally, A.V., Redding, T.W. Proc. Natl. Acad. Sci. U.S.A. (1985) [Pubmed]
  19. Assessing the impact of Cry1Ab-expressing corn pollen on monarch butterfly larvae in field studies. Stanley-Horn, D.E., Dively, G.P., Hellmich, R.L., Mattila, H.R., Sears, M.K., Rose, R., Jesse, L.C., Losey, J.E., Obrycki, J.J., Lewis, L. Proc. Natl. Acad. Sci. U.S.A. (2001) [Pubmed]
  20. HIV-associated lymphoma: promising new results, but with toxicity. Straus, D.J. Blood (2005) [Pubmed]
  21. Females' choice of "good genotypes" as mates is promoted by an insect mating system. Watt, W.B., Carter, P.A., Donohue, K. Science (1986) [Pubmed]
  22. A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Ohnishi, K., Ohno, R., Tomonaga, M., Kamada, N., Onozawa, K., Kuramoto, A., Dohy, H., Mizoguchi, H., Miyawaki, S., Tsubaki, K. Blood (1995) [Pubmed]
  23. Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia. Taub, J.W., Matherly, L.H., Stout, M.L., Buck, S.A., Gurney, J.G., Ravindranath, Y. Blood (1996) [Pubmed]
  24. Highly successful therapeutic vaccinations combining dendritic cells and tumor cells secreting granulocyte macrophage colony-stimulating factor. Driessens, G., Hamdane, M., Cool, V., Velu, T., Bruyns, C. Cancer Res. (2004) [Pubmed]
  25. Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosis. Recher, C., Ysebaert, L., Beyne-Rauzy, O., Mansat-De Mas, V., Ruidavets, J.B., Cariven, P., Demur, C., Payrastre, B., Laurent, G., Racaud-Sultan, C. Cancer Res. (2004) [Pubmed]
  26. Changing trends in allogeneic bone marrow transplantation for leukemia in the 1980s. Bortin, M.M., Horowitz, M.M., Gale, R.P., Barrett, A.J., Champlin, R.E., Dicke, K.A., Gluckman, E., Kolb, H.J., Marmont, A.M., Mrsic, M. JAMA (1992) [Pubmed]
  27. Development of approaches to improve cell survival in myoblast transfer therapy. Qu, Z., Balkir, L., van Deutekom, J.C., Robbins, P.D., Pruchnic, R., Huard, J. J. Cell Biol. (1998) [Pubmed]
  28. Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. Myers, L.A., Patel, D.D., Puck, J.M., Buckley, R.H. Blood (2002) [Pubmed]
  29. Clinical implication of expression of platelet-derived endothelial cell growth factor (PD-ECGF) in metastatic lesions of uterine cervical cancers. Fujimoto, J., Sakaguchi, H., Hirose, R., Wen, H., Tamaya, T. Cancer Res. (1999) [Pubmed]
  30. Altered Ca2+ signaling and mitochondrial deficiencies in hippocampal neurons of trisomy 16 mice: a model of Down's syndrome. Schuchmann, S., Müller, W., Heinemann, U. J. Neurosci. (1998) [Pubmed]
  31. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. Storb, R., Deeg, H.J., Whitehead, J., Appelbaum, F., Beatty, P., Bensinger, W., Buckner, C.D., Clift, R., Doney, K., Farewell, V. N. Engl. J. Med. (1986) [Pubmed]
  32. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. Bensimon, G., Lacomblez, L., Meininger, V. N. Engl. J. Med. (1994) [Pubmed]
  33. Overexpressing Cu/Zn superoxide dismutase enhances survival of transplanted neurons in a rat model of Parkinson's disease. Nakao, N., Frodl, E.M., Widner, H., Carlson, E., Eggerding, F.A., Epstein, C.J., Brundin, P. Nat. Med. (1995) [Pubmed]
  34. Glucocorticoid treatment does not improve neurological recovery following cardiac arrest. Brain Resuscitation Clinical Trial I Study Group. Jastremski, M., Sutton-Tyrrell, K., Vaagenes, P., Abramson, N., Heiselman, D., Safar, P. JAMA (1989) [Pubmed]
  35. Nimodipine after resuscitation from out-of-hospital ventricular fibrillation. A placebo-controlled, double-blind, randomized trial. Roine, R.O., Kaste, M., Kinnunen, A., Nikki, P., Sarna, S., Kajaste, S. JAMA (1990) [Pubmed]
  36. C. elegans mre-11 is required for meiotic recombination and DNA repair but is dispensable for the meiotic G(2) DNA damage checkpoint. Chin, G.M., Villeneuve, A.M. Genes Dev. (2001) [Pubmed]
  37. Murine double nullizygotes of the angiotensin type 1A and 1B receptor genes duplicate severe abnormal phenotypes of angiotensinogen nullizygotes. Tsuchida, S., Matsusaka, T., Chen, X., Okubo, S., Niimura, F., Nishimura, H., Fogo, A., Utsunomiya, H., Inagami, T., Ichikawa, I. J. Clin. Invest. (1998) [Pubmed]
  38. Importance of HLA antigen splits for kidney transplant matching. Opelz, G. Lancet (1988) [Pubmed]
  39. Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Buskens, C.J., Van Rees, B.P., Sivula, A., Reitsma, J.B., Haglund, C., Bosma, P.J., Offerhaus, G.J., Van Lanschot, J.J., Ristimäki, A. Gastroenterology (2002) [Pubmed]
  40. Cooperative action of germ-line mutations in decorin and p53 accelerates lymphoma tumorigenesis. Iozzo, R.V., Chakrani, F., Perrotti, D., McQuillan, D.J., Skorski, T., Calabretta, B., Eichstetter, I. Proc. Natl. Acad. Sci. U.S.A. (1999) [Pubmed]
  41. Current status of cardiac transplantation. Hunt, S.A. JAMA (1998) [Pubmed]
  42. Modulation of murine neuroblastoma in nude mice by opioid antagonists. Zagon, I.S., McLaughlin, P.J. J. Natl. Cancer Inst. (1987) [Pubmed]
  43. Renal transplantation update. Fine, R.N., Terasaki, P.I., Ettenger, R.B., Danovitch, G., Ehrlich, R.M. Ann. Intern. Med. (1984) [Pubmed]
  44. Long-term oxygen therapy. Anthonisen, N.R. Ann. Intern. Med. (1983) [Pubmed]
  45. Epidemiology and early diagnosis of primary liver cancer in China. Yen, F.S., Shen, K.N. Adv. Cancer Res. (1986) [Pubmed]
WikiGenes - Universities